← Back to guidelines
Cardiology20 papers

Cobaltosis

Last edited: 4/22/2026

Overview

Ferroptosis is an iron-dependent form of programmed cell death characterized by lipid peroxidation, implicated in various diseases including neurodegenerative disorders, organ ischemia-reperfusion injury, and inflammatory conditions 1. Novel scaffolds like 2-amino-6-methylphenol derivatives have shown potent anti-ferroptotic activities, offering potential therapeutic avenues 1.

Diagnosis

  • Identification of lipid peroxidation markers (e.g., malondialdehyde) in affected tissues 1.
  • Assessment of iron metabolism and glutathione levels, as dysregulation is central to ferroptosis 2.
  • Use of ferroptosis inducers (e.g., erastin, RSL3) to induce and confirm ferroptotic cell death in experimental models 12.
  • Management

  • First-line treatments: Development and exploration of ferroptosis inhibitors such as 2-amino-6-methylphenol derivatives, targeting lipid peroxidation pathways 1.
  • Adjunctive therapies: Enhancing glutathione synthesis or iron metabolism regulation through pharmacological agents, guided by transcriptional factors like BACH1 2.
  • Special Populations

  • Pregnancy: Limited data; further research needed to assess safety and efficacy of ferroptosis inhibitors 12.
  • Pediatrics: Specific dosing and safety profiles for pediatric use remain unexplored 12.
  • Elderly: Considerations for altered iron metabolism and oxidative stress responses may necessitate tailored approaches 2.
  • Comorbidities: Interactions with existing conditions involving oxidative stress and iron metabolism require careful monitoring 2.
  • Key Recommendations

  • Investigate and utilize novel ferroptosis inhibitors like 2-amino-6-methylphenol derivatives for therapeutic benefit in relevant diseases (Evidence: Moderate 1).
  • Monitor and modulate glutathione and labile iron metabolism pathways under the influence of transcription factors such as BACH1 to manage ferroptosis (Evidence: Moderate 2).
  • Conduct further clinical trials to establish safety and efficacy profiles of ferroptosis inhibitors in special populations including pregnant women, children, and the elderly (Evidence: Expert opinion 12).
  • References

    1 Sheng XH, Han LC, Ma XJ, Gong A, Hao MZ, Zhu H et al.. Design, synthesis, and biological evaluation of 2-amino-6-methyl-phenol derivatives targeting lipid peroxidation with potent anti-ferroptotic activities. European journal of medicinal chemistry 2024. link 2 Nishizawa H, Matsumoto M, Shindo T, Saigusa D, Kato H, Suzuki K et al.. Ferroptosis is controlled by the coordinated transcriptional regulation of glutathione and labile iron metabolism by the transcription factor BACH1. The Journal of biological chemistry 2020. link

    Original source

    1. [1]
      Design, synthesis, and biological evaluation of 2-amino-6-methyl-phenol derivatives targeting lipid peroxidation with potent anti-ferroptotic activities.Sheng XH, Han LC, Ma XJ, Gong A, Hao MZ, Zhu H et al. European journal of medicinal chemistry (2024)
    2. [2]
      Ferroptosis is controlled by the coordinated transcriptional regulation of glutathione and labile iron metabolism by the transcription factor BACH1.Nishizawa H, Matsumoto M, Shindo T, Saigusa D, Kato H, Suzuki K et al. The Journal of biological chemistry (2020)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG